6533b829fe1ef96bd128acfb
RESEARCH PRODUCT
Ketamine in acute phase of severe traumatic brain injury “an old drug for new uses?”
Daniel Agustin GodoyRafael BadenesPaolo PelosiChiara Robbasubject
DrugSecondary insultmedicine.medical_specialtyTime FactorsIntracranial PressureTraumatic brain injurySedationmedia_common.quotation_subjectCritical Care and Intensive Care MedicineNeuroprotectionCooperative sedation03 medical and health sciencesViewpointTraumatic brain injury0302 clinical medicinePharmacokineticsBrain Injuries TraumaticmedicineHumansHypnotics and SedativesKetamineIntensive care medicineIntracranial pressuremedia_commonAnesthetics DissociativeAgitationbusiness.industrylcsh:Medical emergencies. Critical care. Intensive care. First aid030208 emergency & critical care medicinelcsh:RC86-88.9medicine.diseaseNeuroprotectionSafety profileSedationKetaminemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugdescription
AbstractMaintaining an adequate level of sedation and analgesia plays a key role in the management of traumatic brain injury (TBI). To date, it is unclear which drug or combination of drugs is most effective in achieving these goals. Ketamine is an agent with attractive pharmacological and pharmacokinetics characteristics. Current evidence shows that ketamine does not increase and may instead decrease intracranial pressure, and its safety profile makes it a reliable tool in the prehospital environment. In this point of view, we discuss different aspects of the use of ketamine in the acute phase of TBI, with its potential benefits and pitfalls.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-06 | Critical Care |